(Q42614808)

3 November 2017

title

Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study (English)

1 reference

3 November 2017

J Seguí

1

1 reference

3 November 2017

F López-Muñoz

2

1 reference

3 November 2017

C Alamo

3

1 reference

3 November 2017

X Camarasa

4

1 reference

3 November 2017

P García-García

5

1 reference

3 November 2017

A Pardo

6

1 reference

3 November 2017

language of work or name

English

0 references

publication date

12 March 2009

1 reference

Journal of Psychopharmacology

3 November 2017

published in

1 reference

3 November 2017

volume

24

1 reference

3 November 2017

issue

8

1 reference

3 November 2017

page(s)

1201-1207

1 reference

Antidepressant combinations: epidemiological considerations

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Treatment algorithms in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Augmentation strategies for treatment-resistant depression: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Neuropharmacological basis of combining antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

To combine or not to combine? A literature review of antidepressant combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Is treatment-resistant depression a unique subtype of depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Duloxetine: a review of its use in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Combining Antidepressants for Treatment-Resistant Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Reboxetine addition in patients with mirtazapine-resistant depression: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Effect of reboxetine augmentation in SSRI resistant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Treatment-resistant depression: resistant to definition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Efficacy and tolerability of reboxetine in depressive patients treated in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Augmentation strategies in patients with refractory depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

The combination of duloxetine and bupropion for treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Combined antidepressants: clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Potentiation strategies for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Reboxetine adjunct for partial or nonresponders to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Treatment-resistant depression: critique of current approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Use of bupropion in combination with serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

Duloxetine Efficacy for Major Depressive Disorder in Male vs. Female Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881109102641

21 January 2018

Identifiers

DOI

10.1177/0269881109102641

1 reference

3 November 2017

1 reference